Basic Genetics and Immunology of Candida Infections

Infectious Disease Clinics of North America

Volumn 30, Issue 1, 2016, Pages 85-102

  Wang, Xiaowen ^a,b   van de Veerdonk, Frank L ^a   Netea, Mihai G ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b PEKING UNIVERSITY FIRST HOSPITAL   (China)

Author keywords

Candida; Candidiasis; Genetics; Immunology

Indexed keywords

CANDIDIASIS; DISEASE ASSOCIATION; FUNGAL GENETICS; GENETIC POLYMORPHISM; GENETIC PREDISPOSITION; GENETIC SCREENING; HUMAN; IMMUNE DEFICIENCY; IMMUNOLOGY; INVASIVE CANDIDIASIS; MUCOCUTANEOUS CANDIDIASIS; NEUTROPHIL; NONHUMAN; PATHOGENESIS; REVIEW; TH17 CELL; CANDIDA; GENETICS;

CANDIDA; CANDIDIASIS; GENETIC PREDISPOSITION TO DISEASE; HUMANS;

EID: 84958173082     PISSN: 08915520     EISSN: 15579824     Source Type: Journal    
DOI: 10.1016/j.idc.2015.10.010     Document Type: Review

References (100)

1. Das I., Nightingale P., Patel M., et al. Epidemiology, clinical characteristics, and outcome of candidemia: Experience in a tertiary referral center in the UK. Int J Infect Dis 2011, 15(11):e759-e763.
2. Lilic D. New perspectives on the immunology of chronic mucocutaneous candidiasis. Curr Opin Infect Dis 2002, 15(2):143-147.
3. Puel A., Cypowyj S., Marodi L., et al. Inborn errors of human IL-17 immunity underlie chronic mucocutaneous candidiasis. Curr Opin Allergy Clin Immunol 2012, 12(6):616-622.
4. Glocker E.O., Hennigs A., Nabavi M., et al. A homozygous CARD9 mutation in a family with susceptibility to fungal infections. N Engl J Med 2009, 361(18):1727-1735.
5. Romani L. Immunity to fungal infections. Nat Rev Immunol 2011, 11(4):275-288.
6. Drummond R.A., Saijo S., Iwakura Y., et al. The role of Syk/CARD9 coupled C-type lectins in antifungal immunity. Eur J Immunol 2011, 41(2):276-281.
7. Liu L., Okada S., Kong X.F., et al. Gain-of-function human STAT1 mutations impair IL-17 immunity and underlie chronic mucocutaneous candidiasis. J Exp Med 2011, 208(8):1635-1648.
8. van de Veerdonk F.L., Plantinga T.S., Hoischen A., et al. STAT1 mutations in autosomal dominant chronic mucocutaneous candidiasis. N Engl J Med 2011, 365(1):54-61.
9. Smeekens S.P., Plantinga T.S., van de Veerdonk F.L., et al. STAT1 hyperphosphorylation and defective IL12R/IL23R signaling underlie defective immunity in autosomal dominant chronic mucocutaneous candidiasis. PLoS One 2011, 6(12):e29248.
10. Hori T., Ohnishi H., Teramoto T., et al. Autosomal-dominant chronic mucocutaneous candidiasis with STAT1-mutation can be complicated with chronic active hepatitis and hypothyroidism. J Clin Immunol 2012, 32(6):1213-1220.
11. Takezaki S., Yamada M., Kato M., et al. Chronic mucocutaneous candidiasis caused by a gain-of-function mutation in the STAT1 DNA-binding domain. J Immunol 2012, 189(3):1521-1526.
12. Soltesz B., Toth B., Shabashova N., et al. New and recurrent gain-of-function STAT1 mutations in patients with chronic mucocutaneous candidiasis from eastern and central Europe. J Med Genet 2013, 50(9):567-578.
13. Mizoguchi Y., Tsumura M., Okada S., et al. Simple diagnosis of STAT1 gain-of-function alleles in patients with chronic mucocutaneous candidiasis. J Leukoc Biol 2014, 95(4):667-676.
14. Yamazaki Y., Yamada M., Kawai T., et al. Two novel gain-of-function mutations of STAT1 responsible for chronic mucocutaneous candidiasis disease: Impaired production of IL-17a and IL-22, and the presence of anti-IL-17F autoantibody. J Immunol 2014, 193(10):4880-4887.
15. Najjar I., Fagard R. STAT1 and pathogens, not a friendly relationship. Biochimie 2010, 92(5):425-444.
16. Sampaio E.P., Hsu A.P., Pechacek J., et al. Signal transducer and activator of transcription 1 (STAT1) gain-of-function mutations and disseminated coccidioidomycosis and histoplasmosis. J Allergy Clin Immunol 2013, 131(6):1624-1634.
17. Wang X., Lin Z., Gao L., et al. Exome sequencing reveals a signal transducer and activator of transcription 1 (STAT1) mutation in a child with recalcitrant cutaneous fusariosis. J Allergy Clin Immunol 2013, 131(4):1242-1243.
18. Kumar N., Hanks M.E., Chandrasekaran P., et al. Gain-of-function signal transducer and activator of transcription 1 (STAT1) mutation-related primary immunodeficiency is associated with disseminated mucormycosis. J Allergy Clin Immunol 2014, 134(1):236-239.
19. Lee P.P., Mao H., Yang W., et al. Penicillium marneffei infection and impaired IFN-gamma immunity in humans with autosomal-dominant gain-of-phosphorylation STAT1 mutations. J Allergy Clin Immunol 2014, 133(3):894-896.e5.
20. Aldave J.C., Cachay E., Nunez L., et al. A 1-year-old girl with a gain-of-function STAT1 mutation treated with hematopoietic stem cell transplantation. J Clin Immunol 2013, 33(8):1273-1275.
21. Wildbaum G., Shahar E., Katz R., et al. Continuous G-CSF therapy for isolated chronic mucocutaneous candidiasis: Complete clinical remission with restoration of IL-17 secretion. J Allergy Clin Immunol 2013, 132(3):761-764.
22. Higgins E., Al Shehri T., McAleer M.A., et al. Use of ruxolitinib to successfully treat chronic mucocutaneous candidiasis caused by gain-of-function signal transducer and activator of transcription 1 (STAT1) mutation. J Allergy Clin Immunol 2015, 135(2):551-553.
23. van de Veerdonk F.L., Koenen H.J., van der Velden W.J., et al. Immunotherapy with G-CSF in patients with chronic mucocutaneous candidiasis. Immunol Lett 2015, 167(1):54-56.
24. Gu C., Wu L., Li X. Il-17 family: Cytokines, receptors and signaling. Cytokine 2013, 64(2):477-485.
25. Puel A., Cypowyj S., Bustamante J., et al. Chronic mucocutaneous candidiasis in humans with inborn errors of interleukin-17 immunity. Science 2011, 332(6025):65-68.
26. Ling Y., Cypowyj S., Aytekin C., et al. Inherited IL-17RC deficiency in patients with chronic mucocutaneous candidiasis. J Exp Med 2015, 212(5):619-631.
27. Boisson B., Wang C., Pedergnana V., et al. An ACT1 mutation selectively abolishes interleukin-17 responses in humans with chronic mucocutaneous candidiasis. Immunity 2013, 39(4):676-686.
28. Davis S.D., Schaller J., Wedgwood R.J. Job's syndrome. Recurrent, "cold", staphylococcal abscesses. Lancet 1966, 1(7445):1013-1015.
29. Holland S.M., DeLeo F.R., Elloumi H.Z., et al. STAT3 mutations in the hyper-IgE syndrome. N Engl J Med 2007, 357(16):1608-1619.
30. Minegishi Y., Saito M., Tsuchiya S., et al. Dominant-negative mutations in the DNA-binding domain of STAT3 cause hyper-IgE syndrome. Nature 2007, 448(7157):1058-1062.
31. Farmand S., Sundin M. Hyper-IgE syndromes: Recent advances in pathogenesis, diagnostics and clinical care. Curr Opin Hematol 2015, 22(1):12-22.
32. Saito M., Nagasawa M., Takada H., et al. Defective IL-10 signaling in hyper-IgE syndrome results in impaired generation of tolerogenic dendritic cells and induced regulatory T cells. J Exp Med 2011, 208(2):235-249.
33. Ma C.S., Avery D.T., Chan A., et al. Functional STAT3 deficiency compromises the generation of human T follicular helper cells. Blood 2012, 119(17):3997-4008.
34. Engelhardt K.R., McGhee S., Winkler S., et al. Large deletions and point mutations involving the dedicator of cytokinesis 8 (DOCK8) in the autosomal-recessive form of hyper-IgE syndrome. J Allergy Clin Immunol 2009, 124(6):1289-1302.e4.
35. Sabry A., Hauk P.J., Jing H., et al. Vaccine strain varicella-zoster virus-induced central nervous system vasculopathy as the presenting feature of DOCK8 deficiency. J Allergy Clin Immunol 2014, 133(4):1225-1227.
36. Aydin S.E., Kilic S.S., Aytekin C., et al. DOCK8 deficiency: Clinical and immunological phenotype and treatment options - a review of 136 patients. J Clin Immunol 2015, 35(2):189-198.
37. Engelhardt K.R., Gertz M.E., Keles S., et al. The extended clinical phenotype of 64 patients with dedicator of cytokinesis 8 deficiency. J Allergy Clin Immunol 2015, 136(2):402-412.
38. Zhang Q., Davis J.C., Lamborn I.T., et al. Combined immunodeficiency associated with DOCK8 mutations. N Engl J Med 2009, 361(21):2046-2055.
39. Su H.C. Dedicator of cytokinesis 8 (DOCK8) deficiency. Curr Opin Allergy Clin Immunol 2010, 10(6):515-520.
40. Bittner T.C., Pannicke U., Renner E.D., et al. Successful long-term correction of autosomal recessive hyper-IgE syndrome due to DOCK8 deficiency by hematopoietic stem cell transplantation. Klin Padiatr 2010, 222(6):351-355.
41. McDonald D.R., Massaad M.J., Johnston A., et al. Successful engraftment of donor marrow after allogeneic hematopoietic cell transplantation in autosomal-recessive hyper-IgE syndrome caused by dedicator of cytokinesis 8 deficiency. J Allergy Clin Immunol 2010, 126(6):1304-1305.e3.
42. Gatz S.A., Benninghoff U., Schutz C., et al. Curative treatment of autosomal-recessive hyper-IgE syndrome by hematopoietic cell transplantation. Bone Marrow Transplant 2011, 46(4):552-556.
43. Metin A., Tavil B., Azik F., et al. Successful bone marrow transplantation for DOCK8 deficient hyper IgE syndrome. Pediatr Transplant 2012, 16(4):398-399.
44. Kawaguch K., Matsubara K., Uchida Y., et al. Successful treatment with allogenic hematopoietic stem cell transplantation of a severe congenital neutropenia patient harboring a novel ELANE mutation. Rinsho Ketsueki 2014, 55(11):2294-2299.
45. Finnish-German A.C. An autoimmune disease, APECED, caused by mutations in a novel gene featuring two PHD-type zinc-finger domains. Nat Genet 1997, 17(4):399-403.
46. Puel A., Doffinger R., Natividad A., et al. Autoantibodies against IL-17A, IL-17F, and IL-22 in patients with chronic mucocutaneous candidiasis and autoimmune polyendocrine syndrome type I. J Exp Med 2010, 207(2):291-297.
47. Kisand K., Boe Wolff A.S., Podkrajsek K.T., et al. Chronic mucocutaneous candidiasis in APECED or thymoma patients correlates with autoimmunity to Th17-associated cytokines. J Exp Med 2010, 207(2):299-308.
48. Fieschi C., Dupuis S., Catherinot E., et al. Low penetrance, broad resistance, and favorable outcome of interleukin 12 receptor beta1 deficiency: Medical and immunological implications. J Exp Med 2003, 197(4):527-535.
49. Ouederni M., Sanal O., Ikinciogullari A., et al. Clinical features of candidiasis in patients with inherited interleukin 12 receptor beta1 deficiency. Clin Infect Dis 2014, 58(2):204-213.
50. de Beaucoudrey L., Samarina A., Bustamante J., et al. Revisiting human IL-12Rbeta1 deficiency: A survey of 141 patients from 30 countries. Medicine 2010, 89(6):381-402.
51. Minegishi Y., Saito M., Morio T., et al. Human tyrosine kinase 2 deficiency reveals its requisite roles in multiple cytokine signals involved in innate and acquired immunity. Immunity 2006, 25(5):745-755.
52. Kilic S.S., Hacimustafaoglu M., Boisson-Dupuis S., et al. A patient with tyrosine kinase 2 deficiency without hyper-IgE syndrome. J Pediatr 2012, 160(6):1055-1057.
53. Kreins A.Y., Ciancanelli M.J., Okada S., et al. Human TYK2 deficiency: Mycobacterial and viral infections without hyper-IgE syndrome. J Exp Med 2015, 212(10):1641-1662.
54. Okada S., Markle J.G., Deenick E.K., et al. Immunodeficiencies. Impairment of immunity to Candida and Mycobacterium in humans with bi-allelic RORC mutations. Science 2015, 349(6248):606-613.
55. Perez de Diego R., Sanchez-Ramon S., Lopez-Collazo E., et al. Genetic errors of the human caspase recruitment domain-B-cell lymphoma 10-mucosa-associated lymphoid tissue lymphoma-translocation gene 1 (CBM) complex: Molecular, immunologic, and clinical heterogeneity. J Allergy Clin Immunol 2015, [Epub ahead of print].
56. Sakaguchi S., Sakaguchi N., Asano M., et al. Immunologic self-tolerance maintained by activated T cells expressing IL-receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. J Immunol 1995, 155(3):1151-1164.
57. Sharfe N., Nahum A., Newell A., et al. Fatal combined immunodeficiency associated with heterozygous mutation in STAT1. J Allergy Clin Immunol 2014, 133(3):807-817.
58. Feske S., Gwack Y., Prakriya M., et al. A mutation in Orai1 causes immune deficiency by abrogating CRAC channel function. Nature 2006, 441(7090):179-185.
59. Morgan N.V., Goddard S., Cardno T.S., et al. Mutation in the TCRα subunit constant gene (TRAC) leads to a human immunodeficiency disorder characterized by a lack of TCRαβ+ T cells. J Clin Invest 2011, 121(2):695-702.
60. Ouederni M., Vincent Q.B., Frange P., et al. Major histocompatibility complex class II expression deficiency caused by a RFXANK founder mutation: A survey of 35 patients. Blood 2011, 118(19):5108-5118.
61. Picard C., Casanova J.L., Puel A. Infectious diseases in patients with IRAK-4, Myd88, NEMO, or IkappaBalpha deficiency. Clin Microbiol Rev 2011, 24(3):490-497.
62. Abdollahpour H., Appaswamy G., Kotlarz D., et al. The phenotype of human STK4 deficiency. Blood 2012, 119(15):3450-3457.
63. Nehme N.T., Pachlopnik Schmid J., Debeurme F., et al. MST1 mutations in autosomal recessive primary immunodeficiency characterized by defective naive T-cell survival. Blood 2012, 119(15):3458-3468.
64. Schimke L.F., Rieber N., Rylaarsdam S., et al. A novel gain-of-function IKBA mutation underlies ectodermal dysplasia with immunodeficiency and polyendocrinopathy. J Clin Immunol 2013, 33(6):1088-1099.
65. Puck J.M. Neonatal screening for severe combined immunodeficiency. Curr Opin Pediatr 2011, 23(6):667-673.
66. Kuijpers T.W., Ijspeert H., van Leeuwen E.M., et al. Idiopathic CD4+ T lymphopenia without autoimmunity or granulomatous disease in the slipstream of RAG mutations. Blood 2011, 117(22):5892-5896.
67. Li F.Y., Chaigne-Delalande B., Kanellopoulou C., et al. Second messenger role for Mg2+ revealed by human T-cell immunodeficiency. Nature 2011, 475(7357):471-476.
68. Gorska M.M., Alam R. A mutation in the human uncoordinated 119 gene impairs TCR signaling and is associated with CD4 lymphopenia. Blood 2012, 119(6):1399-1406.
69. Drewniak A., Gazendam R.P., Tool A.T., et al. Invasive fungal infection and impaired neutrophil killing in human CARD9 deficiency. Blood 2013, 121(13):2385-2392.
70. Gavino C., Cotter A., Lichtenstein D., et al. CARD9 deficiency and spontaneous central nervous system candidiasis: Complete clinical remission with GM-CSF therapy. Clin Infect Dis 2014, 59(1):81-84.
71. Lanternier F., Mahdaviani S.A., Barbati E., et al. Inherited CARD9 deficiency in otherwise healthy children and adults with Candida species-induced meningoencephalitis, colitis, or both. J Allergy Clin Immunol 2015, 135(6):1558-1568.e2.
72. Lanternier F., Barbati E., Meinzer U., et al. Inherited CARD9 deficiency in 2 unrelated patients with invasive Exophiala infection. J Infect Dis 2015, 211(8):1241-1250.
73. Lanternier F., Pathan S., Vincent Q.B., et al. Deep dermatophytosis and inherited CARD9 deficiency. N Engl J Med 2013, 369(18):1704-1714.
74. Wang X., Wang W., Lin Z., et al. CARD9 mutations linked to subcutaneous phaeohyphomycosis and Th17 cell deficiencies. J Allergy Clin Immunol 2014, 133(3):905-908.e3.
75. Jachiet M., Lanternier F., Rybojad M., et al. Posaconazole treatment of extensive skin and nail dermatophytosis due to autosomal recessive deficiency of CARD9. JAMA Dermatol 2015, 151(2):192-194.
76. Winkelstein J.A., Marino M.C., Johnston R.B., et al. Chronic granulomatous disease. Report on a national registry of 368 patients. Medicine 2000, 79(3):155-169.
77. Dale D.C., Person R.E., Bolyard A.A., et al. Mutations in the gene encoding neutrophil elastase in congenital and cyclic neutropenia. Blood 2000, 96(7):2317-2322.
78. Klein C., Grudzien M., Appaswamy G., et al. HAX1 deficiency causes autosomal recessive severe congenital neutropenia (Kostmann disease). Nat Genet 2007, 39(1):86-92.
79. Fischer A., Lisowska-Grospierre B., Anderson D.C., et al. Leukocyte adhesion deficiency: Molecular basis and functional consequences. Immunodefic Rev 1988, 1(1):39-54.
80. Ferwerda B., Ferwerda G., Plantinga T.S., et al. Human dectin-deficiency and mucocutaneous fungal infections. N Engl J Med 2009, 361(18):1760-1767.
81. Plantinga T.S., van der Velden W.J., Ferwerda B., et al. Early stop polymorphism in human dectin-is associated with increased Candida colonization in hematopoietic stem cell transplant recipients. Clin Infect Dis 2009, 49(5):724-732.
82. Rosentul D.C., Plantinga T.S., Oosting M., et al. Genetic variation in the dectin-1/CARD9 recognition pathway and susceptibility to candidemia. J Infect Dis 2011, 204(7):1138-1145.
83. Nahum A., Dadi H., Bates A., et al. The l412f variant of toll-like receptor 3 (TLR3) is associated with cutaneous candidiasis, increased susceptibility to cytomegalovirus, and autoimmunity. J Allergy Clin Immunol 2011, 127(2):528-531.
84. Nahum A., Dadi H., Bates A., et al. The biological significance of TLR3 variant, L412F, in conferring susceptibility to cutaneous candidiasis, CMV and autoimmunity. Autoimmun Rev 2012, 11(5):341-347.
85. Babula O., Lazdane G., Kroica J., et al. Relation between recurrent vulvovaginal candidiasis, vaginal concentrations of mannose-binding lectin, and a mannose-binding lectin gene polymorphism in Latvian women. Clin Infect Dis 2003, 37(5):733-737.
86. Giraldo P.C., Babula O., Goncalves A.K., et al. Mannose-binding lectin gene polymorphism, vulvovaginal candidiasis, and bacterial vaginosis. Obstet Gynecol 2007, 109(5):1123-1128.
87. van Till J.W., Modderman P.W., de Boer M., et al. Mannose-binding lectin deficiency facilitates abdominal Candida infections in patients with secondary peritonitis. Clin Vaccine Immunol 2008, 15(1):65-70.
88. Lev-Sagie A., Prus D., Linhares I.M., et al. Polymorphism in a gene coding for the inflammasome component NALP3 and recurrent vulvovaginal candidiasis in women with vulvar vestibulitis syndrome. Am J Obstet Gynecol 2009, 200(3):303.e1-303.e6.
89. Wojtowicz A., Tissot F., Lamoth F., et al. Polymorphisms in tumor necrosis factor-alpha increase susceptibility to intra-abdominal Candida infection in high-risk surgical ICU patients. Crit Care Med 2014, 42(4):e304-e308.
90. Choi E.H., Foster C.B., Taylor J.G., et al. Association between chronic disseminated candidiasis in adult acute leukemia and common IL4 promoter haplotypes. J Infect Dis 2003, 187(7):1153-1156.
91. Babula O., Lazdane G., Kroica J., et al. Frequency of interleukin-(IL-4) -589 gene polymorphism and vaginal concentrations of IL-4, nitric oxide, and mannose-binding lectin in women with recurrent vulvovaginal candidiasis. Clin Infect Dis 2005, 40(9):1258-1262.
92. Nahum A., Bates A., Sharfe N., et al. Association of the lymphoid protein tyrosine phosphatase, R620W variant, with chronic mucocutaneous candidiasis. J Allergy Clin Immunol 2008, 122(6):1220-1222.
93. Jurevic R.J., Bai M., Chadwick R.B., et al. Single-nucleotide polymorphisms (SNPS) in human beta-defensin 1: High-throughput SNP assays and association with Candida carriage in type I diabetics and nondiabetic controls. J Clin Microbiol 2003, 41(1):90-96.
94. Plantinga T.S., Johnson M.D., Scott W.K., et al. Toll-like receptor 1 polymorphisms increase susceptibility to candidemia. J Infect Dis 2012, 205(6):934-943.
95. Woehrle T., Du W., Goetz A., et al. Pathogen specific cytokine release reveals an effect of TLR2 Arg753Gln during Candida sepsis in humans. Cytokine 2008, 41(3):322-329.
96. Van der Graaf C.A., Netea M.G., Morre S.A., et al. Toll-like receptor 4 Asp299Gly/Thr399Ile polymorphisms are a risk factor for Candida bloodstream infection. Eur Cytokine Netw 2006, 17(1):29-34.
97. Johnson M.D., Plantinga T.S., van de Vosse E., et al. Cytokine gene polymorphisms and the outcome of invasive candidiasis: A prospective cohort study. Clin Infect Dis 2012, 54(4):502-510.
98. Jaeger M., van der Lee R., Cheng S.C., et al. The RIG-I-like helicase receptor mda5 (IFIH1) is involved in the host defense against Candida infections. Eur J Clin Microbiol Infect Dis 2015, 34(5):963-974.
99. Smeekens S.P., Ng A., Kumar V., et al. Functional genomics identifies type I interferon pathway as central for host defense against Candida albicans. Nat Commun 2013, 4:1342.
100. Kumar V., Cheng S.C., Johnson M.D., et al. Immunochip SNP array identifies novel genetic variants conferring susceptibility to candidaemia. Nat Commun 2014, 5:4675.